



FOR IMMEDIATE RELEASE

Sapio Sciences Announces Exemplar LIMS v2 Licensed By ExonHit Therapeutics

York, PA – February 26, 2008 – Sapio Sciences is pleased to announce that ExonHit Therapeutics, world's leader in the analysis of alternative RNA splicing, has licensed Exemplar LIMS v2. Driving the need for a LIMS was ExonHit's desire to comply with GLP standards and to track all aspects of their splice-array experiments.

Heather Jordan, Director of Operations at ExonHit says, "Exemplar LIMS flexibility will allow us to easily customize it in support of our complex workflows and to track key data points in any protocol and to also track samples and their related clinical and phenotypic values. We are also looking forward to working with the plug-in architecture, which will enable us to integrate with other applications and equipment. ExonHit is moving towards GLP compliance, and Exemplar LIMS will make compliance with GLP standards a smooth process."

"We are pleased that ExonHit has chosen Exemplar LIMS.", says Kevin Cramer, VP of Sales at Sapio, "ExonHit's need for GLP compliance and their selection of Sapio validates Exemplar LIMS flexibility and robustness for use in a demanding commercial laboratory environment. We look forward to working with Ms. Jordan and her team as they move towards full GLP compliance and through their software validation process."

Sapio Sciences Exemplar LIMS v2 is available immediately. For more information or to schedule a product demonstration, visit <http://www.SapioSciences.com>.

About Sapio Sciences LLC

Sapio Sciences is a leading provider of LIMS and Data Management software, enabling scientists to manage samples, protocols and clinical trials. Sapio will continue to break new ground in ease of use and breadth of functionality across its product line, enabling organizations to reduce costs while increasing productivity and efficiency of both laboratories and researchers alike. Sapio has strong working relationships with Affymetrix, Illumina, Applied Biosystems, Expression Analysis and Genome Explorations ensuring compatibility with technology from these leading companies.

About ExonHit Therapeutics

<http://www.exonhit.com/>

ExonHit Therapeutics is the world's leader in the analysis of alternative RNA splicing, a process which when deregulated plays a key role in the onset of various diseases.

ExonHit has a multi-component commercial strategy to capture the maximum value from its leadership in alternative splicing. The Company is already generating revenues from a new generation of microarrays, SpliceArray™ family of products that enable life science researchers to detect crucial disease-associated information. These products are marketed worldwide in conjunction with Agilent and Affymetrix. In the field of diagnostics, ExonHit has a major collaboration with bioMérieux to develop completely novel predictive blood-based cancer diagnostics, which could play a key role in improving the treatment of breast cancer and other major cancers and develops its own projects for the detection of other chronic diseases such as Alzheimer's disease or atherosclerosis.

In parallel, ExonHit is developing its own therapeutic pipeline in the field of neurodegenerative diseases and cancer. The Company has advanced drug candidates into clinical trials and is evaluating several promising pre-clinical compounds. ExonHit also has a strategic partnership with Allergan, to discover and develop new therapeutics in the areas of pain, neurological diseases and ophthalmology. This collaboration provides on-going research funding to ExonHit.

Founded in 1997, ExonHit is headquartered in Paris, France and has a U.S. facility in Gaithersburg, Maryland. The Company is listed on Alternext of Euronext Paris (ticker: ALEHT; ISIN: FR0004054427) since November 17, 2005.

For Further Information:

Sapio Sciences LLC
Ms. Christine Carolen
Tel: (717) 870-9257
Email: ccarolen@sapiosciences.com